ArticleOncology letters2018
Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Immune signature of gene expression pattern shared by autism spectrum disorder and Huntington's disease.IBRO neuroscience reports · 2024Article
- The Role of Small Interfering RNAs in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2024Review
- The Theory ofGenes · 2022Article
- MicroRNA-27a-5p Inhibits Proliferation, Migration, and Invasion and Promotes Apoptosis of Wilms' Tumor Cell by Targeting PBOV1.Molecular and cellular biology · 2022Article
- Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters.Frontiers in oncology · 2020Review
- Prognostic value ofOncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate and breast cancer overexpressed 1 (PBOV1) is a known human protein-coding gene with an uncharacterized function; it has been demonstrated to be overexpressed in a variety of human cancer types. The overexpression of PBOV1 has been indicated as significantly associated with the poor prognosis of these types of cancer. However, the function of PBOV1 in hepatocellular carcinoma (HCC) has not yet been elucidated. The present study was designed to evaluate the expression and prognostic significance of PBOV1 in HCC. Reverse transcription-quantitative polymerase chain reaction and western blot analyses were conducted to measure the expression of PBOV1 in HCC cell lines and tissues. The associations between PBOV1 expression and clinicopathological features were statistically analyzed. The association between PBOV1 expression and the prognosis of HCC patients was analyzed by the Kaplan-Meier method. The mRNA and protein expression levels of PBOV1 were significantly increased in the HCC cell lines and HCC tissues (all P<0.05) compared with normal cell lines and tissues. In addition, PBOV1 expression was significantly associated with maximal tumor size (P=0.032), tumor metastasis (P=0.035) and tumor stage (P=0.017). The Kaplan-Meier survival curves indicated that overall survival was significantly poorer in patients with HCC with PBOV1 overexpression (P<0.05) compared with patients with low expression levels. The multivariate analysis indicated that high PBOV1 expression was an independent predictor of poor overall survival. To the best of our knowledge, the data of the present study describes the expression pattern of PBOV1 in HCC for the first time, and also suggests that PBOV1 may serve as a valuable prognostic biomarker for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.